.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,951,964

« Back to Dashboard

Details for Patent: 5,951,964

Title: Technetium-99m labeled peptides for imaging
Abstract:This invention relates to radiolabeled reagents, including specific-binding peptide embodiments thereof, and methods for producing and using such reagents. Specifically, the invention relates to reagents for preparing scintigraphic imaging agents for imaging sites in a mammalian body. Reagents, methods and kits for making such reagents, and methods for using such reagents labeled with technetium-99m (Tc-99m) via Tc-99m binding moieties comprising said reagents, are provided. In particular, the specific-binding peptides and Tc-99m binding moieties comprising the reagents of the invention are covalently linked to a polyvalent linker moiety, so that the polyvalent linker moiety is covalently linked to a multiplicity of the specific-binding peptides, and the Tc-99m binding moieties are covalently linked to a plurality of the specific-binding peptides, the polyvalent linker moiety, or to both the specific-binding peptides and the polyvalent linker moiety.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Filing Date:Jan 26, 1995
Application Number:08/341,537
Claims:1. A reagent for preparing a scintigraphic imaging agent comprising:

a) at least two specific binding peptides, each peptide being covalently linked to a technetium-99m binding moiety; and

b) a polyvalent linker covalently linked to each peptide.

2. A reagent for preparing a scintigraphic imaging agent comprising:

a) at least two specific binding peptides, each peptide being covalently linked to a technetium-99m binding moiety; and

b) a polyvalent linker covalently linked to each moiety.

3. A reagent for preparing a scintigraphic imaging agent comprising:

a) a first specific binding peptide covalently linked to a first technetium-99m binding moiety;

b) a second specific binding peptide covalently linked to a second technetium-99m binding moiety; and

c) a polyvalent linker covalently linked to the first peptide and to the second technetium-99m binding moiety.

4. A reagent for preparing a scintigraphic imaging agent comprising:

a) a first specific binding peptide covalently linked to a first polyvalent linker;

b) a second specific binding peptide covalently linked to a second polyvalent linker; and

c) a technetium-99m binding moiety linking the first linker and the second peptide.

5. A reagent for preparing a scintigraphic imaging agent comprising:

a) at least two specific binding peptides, each peptide being covalently linked to a technetium-99m binding moiety;

b) a first polyvalent linker covalently linked to each peptide; and

c) a second polyvalent linker covalently linked to the first polyvalent linker.

6. A reagent for preparing a scintigraphic imaging agent comprising:

a) at least two specific binding peptides, each peptide being covalently linked to a technetium-99m binding moiety;

b) a first polyvalent linker covalently linked to each moiety; and

c) a second polyvalent linker covalently linked to the first polyvalent linker.

7. A reagent for preparing a scintigraphic imaging agent comprising:

a) at least two specific binding peptides;

b) at least two first polyvalent linkers, wherein each peptide is covalently linked to a first polyvalent linker;

c) a second polyvalent linker covalently linked to each first polyvalent linker; and

d) a technetium-99m binding moiety covalently linked to the second polyvalent linker.

8. A reagent for preparing a scintigraphic imaging agent comprising:

a) at least two specific binding peptides;

b) at least two first polyvalent linkers, wherein each peptide is covalently linked to a first polyvalent linker;

c) at least two technetium-99m binding moieties, each covalently linked to a first polyvalent linker; and

d) a second polyvalent linker covalently linked to each first polyvalent linker.

9. The reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein the moiety is selected from the group consisting of:

I

wherein C(pgp).sup.S is a cysteine having a protected thiol group and (aa) is an amino acid;

II

a technetium-99m binding moiety comprising a single thiol group having a formula:

wherein

A.sup.1 is H, HOOC, H.sub.2 NOC, or --NHOC;

B.sup.1 is SH or NHR.sup.3 ;

X.sup.1 is H, methyl, SH or NHR.sup.3 ;

Z.sup.1 is H or methyl;

R.sup.1 and R.sup.2 are independently H or lower alkyl;

R.sup.3 is H, lower alkyl or --C.dbd.O;

n is 0, 1 or 2;

and where B.sup.1 is NHR.sup.3, X.sup.1 is SH, Z.sup.1 is H and n is 1 or 2;

where X.sup.1 is NHR.sup.3, B.sup.1 is SH, Z.sup.1 is H and n is 1 or 2;

where B.sup.1 is H, A.sup.1 is HOOC, H.sub.2 NOC, or --NHOC, X.sup.1 is SH, Z.sup.1 is H and n is 0 or 1;

where Z.sup.1 is methyl, X.sup.1 is methyl, A.sup.1 is HOOC, H.sub.2 NOC, or --NHOC, B.sup.1 is SH and n is 0; ##STR8## wherein X.sup.2 =H or a protecting group;

(amino acid)=any amino acid; ##STR9## wherein X.sup.2 =H or a protecting group;

(amino acid)=any amino acid; ##STR10## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

each (pgp).sup.S is independently a thiol protecting group or H;

m, n and p are independently 2 or 3;

A.sup.2 =linear or cyclic lower alkyl, aryl, heterocyclyl, a combination thereof or a substituted derivative thereof; and ##STR11## wherein each R is independently H, CH.sub.3 or C.sub.2 H.sub.5 ;

m, n and p are independently 2 or 3;

A.sup.3 =linear or cyclic lower alkyl, aryl, heterocyclyl, a combination thereof or a substituted derivative thereof;

V=H or -CO-peptide;

R.sup.4 =H or peptide;

and wherein when V=H, R.sup.4 =peptide and when R.sup.4 =H, V=-CO-peptide.

10. The reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein each linker comprises at least two functional groups selected from the group consisting of primary amines, secondary amines, hydroxyl groups, carboxylic acid groups, and thiol-reactive groups.

11. The reagent of claim 10, wherein the functional groups are thiol-reactive groups selected from the groups consisting of maleimido groups, chloroacetyl groups, bromoacetyl groups, and iodoacetyl groups.

12. The reagent of claim 10, wherein the linker is selected from the group consisting of bis-succinimidylmethylether, 4-(2,2-dimethylacetyl)benzoic acid, N-[2-(N'N'-bis(2-succinimidoethyl)aminoethyl)]-N.sup.6,N.sup.9 -bis(2-methyl-2-mercaptopropyl)-6,9-diazanonanamide, 4-(2,2-dimethylacetyl)benzoic acid, tris(succinimidylethyl)amine, bis-succinimidohexane, 4-(O-CH.sub.2 CO-Gly-Gly-Cys.arnide)acetophenone, a derivative of bis-succinimidylmethylether, a derivative of 4-(2,2-dimethylacetyl)benzoic acid, a derivative of N-[2-(N',N'-bis(2-succinimidoethyl)aminoethyl)]-N.sup.6,N.sup.9 -bis(2-methyl-2-mercaptopropyl)-6,9-diazanonanamide, a derivative of 4-(2,2-dimethylacetyl)benzoic acid, a derivative of tris(succinimidylethyl)amine, a derivative of bis-succinimidohexane, and a derivative of 4-(O-CH.sub.2 CO-Gly-Gly-Cys.amide)acetophenone.

13. The reagent of claims 1, 2, 3, 4 , 5, 6, 7, or 8, further comprising technetium-99m.

14. A complex formed by reacting the reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8 with technetium-99m and a reducing agent.

15. The complex of claim 14, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion, and a ferrous ion.

16. A complex formed by reacting the reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8 with technetium-99m by ligand exchange of a prereduced technetium-99m complex.

17. A kit for preparing a radiopharmaceutical preparation, said kit comprising a sealed vial containing a predetermined quantity of the reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8 and a sufficient amount of reducing agent to label the reagent with technetium-99m.

18. A method of labeling a reagent according to claims 1, 2, 3, 4, 5, 6, 7, or 8, comprising the step of reacting the reagent with technetium-99m in the presence of a reducing agent.

19. The method of claim 18, wherein the reducing agent is selected from the group consisting of a dithionite ion, a stannous ion and a ferrous ion.

20. A method of imaging a site within a mammalian body comprising the steps of administering an effective diagnostic amount of the reagent of claim 13 and detecting a radioactive signal from the technetium-99m localized at the site.

21. The method of claim 20, wherein the site is a thrombus.

22. The method of claim 20, wherein the site is an infection.

23. The reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein the peptide is chemically synthesized in vitro.

24. The reagent of claim 23, wherein the peptide is synthesized by solid phase peptide synthesis.

25. The reagent of claims 1, 2, 3, 4, 5, 6, 7, or 8, wherein the moiety is covalently linked to the peptide during in vitro chemical synthesis.

26. The reagent of claim 25, wherein the moiety is covalently linked to the peptide during solid phase peptide synthesis.

27. A composition comprising a reagent selected from the group consisting of:

(acetyl.F.sub.D_k PRPG).sub.2 KGGGCamide;

(acetyl.CC.sub.Acm GC.sub.Acm PLYKKIIKKLLES).sub.2 -BSME;

(acetyl.CC.sub.Acm GC.sub.Acm GGPLYKKIIKKLLES ).sub.2 -BSME;

(formyl.MLF(N.sub..epsilon. -BAT)GGC.sub.Acm GC.sub.Acm GGC.amide).sub.2 -BSME;

(GPRPPPGGC.sub.Acm GC.sub.Acm GGCamide).sub.3 -TSEA;

(Pic.SC.sub.Acm SYNRGDSTCamide).sub.3 -TSEA;

(ma.GGGRALVDTLKFVTQAEGAKamide).sub.2 -(BAT-BS); and

(Pic.GC.sub.Acm RALVDTLKFVTQAEGAKCamide).sub.3 -TSEA.

28. The composition of claim 27, further comprising technetium-99m.

29. A kit for preparing a radiopharmaceutical preparation, said kit comprising a sealed vial the composition of claim 27 and a sufficient amount of a reducing agent to label the reagent with technetium-99m.

30. A reagent having a formula: ##STR12## .
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc